Trial Profile
A retrospective study evaluating efficacy of dose reduction of first line pazopanib in patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Aug 2017
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 11 Aug 2017 Results assessing efficacy of dose reduction of first line pazopanib in patients with metastatic renal cell carcinoma published in the Drugs in R and D
- 24 Mar 2017 New trial record
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium.